AU593051B2 - Method of treating alzheimer's disease - Google Patents

Method of treating alzheimer's disease Download PDF

Info

Publication number
AU593051B2
AU593051B2 AU67609/87A AU6760987A AU593051B2 AU 593051 B2 AU593051 B2 AU 593051B2 AU 67609/87 A AU67609/87 A AU 67609/87A AU 6760987 A AU6760987 A AU 6760987A AU 593051 B2 AU593051 B2 AU 593051B2
Authority
AU
Australia
Prior art keywords
galanthamine
disease
alzheimer
acid addition
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU67609/87A
Other languages
English (en)
Other versions
AU6760987A (en
Inventor
Bonnie Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU593051(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU6760987A publication Critical patent/AU6760987A/en
Application granted granted Critical
Publication of AU593051B2 publication Critical patent/AU593051B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU67609/87A 1986-01-15 1987-01-15 Method of treating alzheimer's disease Expired AU593051B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease
US819141 1986-01-15

Publications (2)

Publication Number Publication Date
AU6760987A AU6760987A (en) 1987-07-16
AU593051B2 true AU593051B2 (en) 1990-02-01

Family

ID=25227312

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67609/87A Expired AU593051B2 (en) 1986-01-15 1987-01-15 Method of treating alzheimer's disease

Country Status (10)

Country Link
US (1) US4663318A (enExample)
EP (1) EP0236684B1 (enExample)
JP (1) JPH08778B2 (enExample)
AT (1) ATE76294T1 (enExample)
AU (1) AU593051B2 (enExample)
DE (3) DE10199020I2 (enExample)
ES (1) ES2000428T3 (enExample)
GR (2) GR880300077T1 (enExample)
LU (1) LU90710I2 (enExample)
NL (1) NL300140I2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
EP0787115B1 (de) * 1994-10-21 2000-01-05 Sanochemia Pharmazeutika AG VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
KR100437105B1 (ko) * 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
AU3477900A (en) * 2000-01-28 2001-08-07 Tricia Grose Herbal supplement for cognitive related impairment due to estrogen loss
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
PT1181294E (pt) 2000-03-31 2004-07-30 Sanochemia Pharmazeutika Ag Novos derivados e analogos da galantamina
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
GEP20094759B (en) * 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
CA2527114A1 (en) * 2003-05-30 2004-12-16 Microbia, Inc. Methods for the protection of memory and cognition
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
CA2532347C (en) * 2003-07-25 2012-03-27 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20070166363A1 (en) * 2004-02-19 2007-07-19 Lane Roger M Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2005112908A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function
WO2006004201A1 (ja) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
MX2010010460A (es) 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
MX2012003207A (es) 2009-09-18 2012-05-29 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
BR122016020433A2 (pt) 2012-09-05 2019-08-27 Chase Pharmaceuticals Corp combinação farmacêutica e uso de um nspacha e de um achei e, opcionalmente, de um naaea
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
HK1218623A1 (zh) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 用於改善認知功能的方法和組合物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
DE10199020I1 (de) 2001-05-23
ATE76294T1 (de) 1992-06-15
EP0236684B1 (en) 1992-05-20
EP0236684A2 (en) 1987-09-16
ES2000428T3 (es) 1993-10-01
DE10199020I2 (de) 2004-05-06
GR880300077T1 (en) 1988-10-21
ES2000428A4 (es) 1988-03-01
US4663318A (en) 1987-05-05
EP0236684A3 (en) 1988-12-14
JPH08778B2 (ja) 1996-01-10
GR3005447T3 (enExample) 1993-05-24
NL300140I2 (nl) 2004-04-01
LU90710I2 (fr) 2001-03-05
NL300140I1 (nl) 2004-02-02
JPS62215527A (ja) 1987-09-22
ES2000428T9 (es) 2013-08-14
DE236684T1 (de) 1988-04-28
AU6760987A (en) 1987-07-16
DE3779149D1 (de) 1992-06-25

Similar Documents

Publication Publication Date Title
AU593051B2 (en) Method of treating alzheimer&#39;s disease
CA2226784C (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
JP2963720B2 (ja) 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物
JP2977912B2 (ja) 向精神薬の安定化溶液
US5750537A (en) Use of 5HT3 antagonist to treat impotence
JPH06507621A (ja) ベンゾジアゼピンによる治療における改善
KR19990067527A (ko) 동통의 치료를 위한 에피나스틴의 용도
WO1988003801A1 (en) Medicaments for treatment or prevention of withdrawal syndrome
JPH04501267A (ja) 骨髄造血の刺激に有用なヘテロアリール―３―オキソ―プロパンニトリル誘導体
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
EP0190851B1 (en) Improved antiinflammatory composition
US6274621B1 (en) Ginkgolides for inhibition of membrane expression of benzodiazepine receptors
JP3243514B2 (ja) 療法―抵抗性精神分裂症治療用医薬
AU744261B2 (en) Use of NK-1 receptor antagonists for treating eating disorders
JPH0680009B2 (ja) 抗高血圧組み合わせ医薬
US4363809A (en) Organic compounds
WO1996033723A2 (en) Use of benzamide derivatives for treating and/or preventing meniere&#39;s syndrome and motion sickness
US4152435A (en) Compositions and methods to treat hypertension comprising a pyridazine and N-amidino-2-(2,6-dichlorophenyl) acetamide
US3780180A (en) N-substituted amino-n-nitroso-aminoace-tonitriles in the treatment of hypertension
US4225605A (en) Ergolene or ergoline compounds for treating congestive heart failure
AU724416B2 (en) Ginkgolides for inhibition of membrane expression
JPH11513386A (ja) β−受容体遮断薬とオピオイドとの新規な組合せ物
KR920703593A (ko) 이미다조퀴녹살린 화합물, 이의 제조방법 및 용도
JPH03170434A (ja) 抗ガン剤相乗剤
US3743746A (en) Process of treating peptic ulcer with a non-anticholinergic agent